Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Joan Carles, Cristina Suárez, Carlos Mesía, Miquel Nogué, Albert Font, Montserrat Doménech, Marta Suárez, Ignasi Tusquets, M. Gallén, Joan Albanell, Xavier Fabregat

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Objectives: Cisplatin-based combination chemotherapy is the mainstay of treatment for advanced bladder cancer. However, full doses of cisplatin cannot be delivered in patients with impaired renal function. Our aim was to prove the feasibility of a gemcitabine and low-dose cisplatin regimen, delivered every two weeks in patients with impaired renal function. Material and methods: Patients with locally advanced or metastatic bladder cancer with creatinine clearance between 35-60 ml/min received gemcitabine 2500 mg/m2 and cisplatin 35 mg/m2 on day 1, every 14 days. Results: Between January 2004 and March 2005, 17 patients were treated. Mean creatinine clearance was 47.8 ml/min (range: 37-59 ml/min). Four patients had previously received chemotherapy with gemcitabine and/or platinum. Median number of cycles per patient was 5 (1-13). No patient developed renal toxicity or worsening of renal function. Main toxicities were (grade 3/4): Anemia 2/1; leucopenia: 1/2; trombopenia 1/1. There was one toxic death related to metabolic acidosis, secondary to vomiting. Among 16 patients evaluable for response, we observed one complete response, 7 partial responses (ORR: 53.3%; IC 95%: 28.1-78.5%), 6 stabilizations (37.5%) and 2 progressions (12.5%). Conclusions: Gemcitabine and low-dose cisplastin is a safe and feasible combination in patients with poor renal function. Response rates seem similar to those previously described with standard schedules of this combination. © FESEO 2006.
Original languageEnglish
Pages (from-to)755-757
JournalClinical and Translational Oncology
Volume8
DOIs
Publication statusPublished - 1 Dec 2006

Keywords

  • Bladder cancer
  • Cisplatin
  • Gemcitabine
  • Unfit patients

Fingerprint Dive into the research topics of 'Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function'. Together they form a unique fingerprint.

Cite this